Lumin Health names Aakash Sathappan site director in Brookline

Lumin Health has appointed Aakash Sathappan, MD, as site director of its Brookline, Massachusetts location, where he will oversee care for patients with treatment-resistant depression. The move comes as demand grows for ketamine and insurance-covered esketamine treatment across the U.S., and Lumin Health looks to stand out with a more coordinated outpatient model.

Why it matters: - Lumin Health is adding senior clinical leadership in Brookline as demand rises for ketamine and esketamine treatment for treatment-resistant depression. - The Brookline site is part of Lumin Health’s effort to offer one setting for clinical oversight, protocols and emotional support for patients who have not responded to multiple therapies. - The appointment strengthens access in the Boston region for a treatment model that is now more broadly covered by insurance.

What happened: - Lumin Health appointed Aakash Sathappan, MD, as site director of Lumin Health Brookline, Massachusetts. - Dr. Sathappan will support the clinical team treating patients in the Boston region. - Lumin Health made the announcement on Aug. 5, 2026.

The details: - Dr. Sathappan will oversee clinical care at Lumin Health Brookline. - His role includes care for people living with treatment-resistant depression and related conditions. - Dr. Sathappan will also help coordinate with referring providers. - Lumin Health says the Brookline location is a purpose-built outpatient setting. - The company offers ketamine treatment and insurance-covered esketamine, also known as Spravato. - The company operates five locations across Massachusetts and Maryland. - Lumin Health describes itself as one of the largest U.S. providers of esketamine and ketamine therapy. - Dr. Sathappan is Harvard-trained, board-certified and has published extensively. - He has professional experience at Boston Children’s Hospital. - Dr. Sathappan authored the first informed-consent guidelines for ketamine in adolescents with treatment-resistant depression. - He also serves as course director for Harvard psychiatry fellows and is faculty at Harvard Medical School.

Between the lines: - The appointment signals that Lumin Health is leaning on recognized academic and clinical leadership as more providers enter the ketamine and esketamine market. - The company is positioning its outpatient model as an alternative to fragmented care split between hospital systems and at-home treatment approaches. - Dr. Sathappan’s background in adolescent ketamine guidance suggests Lumin Health may want deeper credibility with complex and younger patient populations.

What's next: - Dr. Sathappan is expected to help standardize care and strengthen referral relationships at the Brookline site. - Lumin Health is likely to continue emphasizing its supervised outpatient model as demand for esketamine and ketamine treatment grows. - More information is available on Lumin Health's website.

The bottom line: - Lumin Health is betting that experienced psychiatric leadership and a tightly managed outpatient setting will help it compete in a fast-growing depression treatment market. - Lumin Health on LinkedIn